• IGF2BP3–FZD1/7 Drives Carboplatin Resistance

  2026-09-04

  A 2025 Cancer Letters study identifies IGF2BP3 as an m6A-dependent regulator of FZD1/7 stability, β-catenin signaling, stem-like properties, and carboplatin resistance in triple-negative breast cancer. The findings support FZD1/7 inhibition as a mechanistically guided strategy for sensitizing TNBC cancer stem cells to platinum treatment, although clinical transferability remains unestablished.

• LRRC8A–Caveolin-1 Signaling in PDAC

  2026-09-04

  The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 complex as a mechanistic bridge between cell-volume regulation, KRAS/EGFR signaling, ribosome biogenesis, and pancreatic ductal adenocarcinoma growth. Its combination of bioinformatics, genetic and pharmacological perturbation, xenografts, and patient-derived organoids provides a framework for studying how membrane organization supports biosynthetic expansion during the cell cycle.

• Isradipine (Dynacirc) Calcium Channel Research

  2026-09-03

  Isradipine (Dynacirc) provides a practical L-type calcium-channel perturbation strategy for separating vascular smooth muscle relaxation from neuronal calcium overload. Its value is greatest when paired with electrophysiology, calcium imaging, and channel-subtype controls rather than treated as a universal blocker.

• Geneticin: Selection Strategy for Plasticity Research

  2026-09-03

  Geneticin, also known as G418 Sulfate, is more than a routine selection reagent: its ribosomal mechanism, marker dependence, and cell-state consequences make it a strategic variable in translational research. This article connects G418 selection with mechanistic studies of EBV-driven nasopharyngeal carcinoma plasticity, cell-line development, and early antiviral workflows while defining practical boundaries for interpretation.

• Oligomycin A Workflow for Mitochondrial Energy Studies

  2026-09-02

  Oligomycin A provides a practical way to separate ATP-linked respiration from broader mitochondrial dysfunction in cancer and cell-death models. This workflow connects acute oxygen-consumption assays with ATP, ROS, viability, and metabolic-adaptation readouts, while addressing formulation and dosing issues that commonly undermine reproducibility.

• Dovitinib (TKI-258) in RTK Cancer Assays

  2026-09-02

  Dovitinib (TKI-258) provides a practical way to interrogate convergent FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling in cancer models. This workflow connects quantitative RTK inhibition with ERK/STAT readouts, apoptosis assays, and the EDI3-centered resistance biology described in HER2-targeted therapy-resistant breast cancer.

• MMP7, EMT, and Liver Fibrosis in Biliary Atresia

  2026-09-01

  A 2026 study identifies MMP7 as a mechanistic driver of biliary atresia-associated liver fibrosis by cleaving E-cadherin and promoting β-catenin nuclear translocation in biliary epithelial cells. Its combination of patient samples, transcriptomic analysis, cell experiments, and chronic biliary atresia mice supports MMP7 blockade as a potential anti-fibrotic strategy while distinguishing this axis from broader Wnt pathway activation.

• SCP4, H3T3 Dephosphorylation, and Chromosome Stability

  2026-09-01

  The reference study identifies nuclear phosphatase SCP4 as a mitotic H3T3 phosphatase that regulates chromosomal passenger complex recruitment and chromosome segregation. Cellular and mouse-zygote experiments connect abnormal SCP4 activity with chromosome missegregation, aneuploidy, and early developmental mitotic failure.

• Syringin: A Translational Edge in RCC Research

  2026-08-31

  Syringin is moving from natural product research toward a more strategic role in renal cell carcinoma investigation. Recent evidence links it to EGFR/PI3K/Akt pathway modulation, apoptosis, reduced RCC cell aggressiveness, and improved sunitinib sensitivity in vitro. This thought-leadership article translates those findings into a practical framework for compound qualification, combination testing, mechanistic validation, and translational decision-making while distinguishing research evidence from clinical claims.

• ISRIB (trans-isomer) for ISR Research Workflows

  2026-08-31

  ISRIB (trans-isomer) gives researchers a mechanistically precise way to test whether PERK–eIF2α signaling drives translational shutdown, ER-stress sensitivity, or memory loss. This workflow-focused guide covers cell assays, apoptosis measurements, brain-relevant studies, formulation, controls, and troubleshooting without treating a single concentration or injection as universally effective.

• WNT Switch Differentiation of Mouse ESCs into Cardiomyocytes

  2026-08-30

  The 2024 Cells study introduces a temporal WNT Switch method that combines early CHIR99021-mediated WNT activation with later XAV939-mediated inhibition to drive mouse embryonic stem cells toward cardiomyocytes. The approach increases beating cardiomyocyte yield while reducing treatment complexity, and it provides a practical framework for studying cardiac development and chemical differentiation control.

• Self-Adaptive Nanocarriers in Pancreatic Cancer

  2026-08-29

  This ACS Nano study presents DATCPT, a pH/reactive oxygen species-responsive camptothecin nanocarrier designed to navigate circulation, tumor binding, extracellular matrix penetration, and metastatic signaling barriers in orthotopic pancreatic cancer. Its self-adaptive arginine chemistry converts the tumor redox environment into a delivery and therapeutic mechanism, offering a framework for interpreting ROS-dependent nanomedicine responses.

• NETs in CML and Differential TKI Effects

  2026-08-28

  This study shows that neutrophil extracellular trap formation is elevated in treatment-naïve chronic myeloid leukemia and is further modulated by tyrosine kinase inhibitors, with ponatinib producing the strongest augmentation in the tested systems. Its combination of patient-derived neutrophils, pathway-directed inhibitors, and a BCR-ABL1-engineered differentiation model provides a mechanistic framework for studying how leukemia biology and TKI-associated vascular risk may intersect.

• Dose- and Time-Dependent Ibotenic Acid Toxicity

  2026-08-28

  A 2026 murine study systematically characterized ibotenic acid toxicity across dose and time, linking behavioral changes with biochemical disturbances, early c-fos activation, and reduced Nissl bodies at high exposure. The findings establish a useful acute toxicology framework while clarifying why systemic poisoning studies should be distinguished from regional lesion paradigms and neurodegenerative disease models.

• Nadolol (SQ-11725): Research Mechanism & Workflow

  2026-08-27

  Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor antagonist for cardiovascular research. Its beta-blocking pharmacology is established, while its reported OATP1A2 substrate status supports transporter-aware pharmacokinetic study design rather than automatic conclusions about tissue exposure.

8649 records 1/577 page Next 12345 下5页 Last page